Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.

Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, Lamping E, Marté JL, Donahue RN, Grenga I, Cordes L, Christensen O, Mahnke L, Helwig C, Gulley JL.

Clin Cancer Res. 2018 Mar 15;24(6):1287-1295. doi: 10.1158/1078-0432.CCR-17-2653. Epub 2018 Jan 3.

PMID:
29298798
2.

Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.

Grenga I, Donahue RN, Gargulak ML, Lepone LM, Roselli M, Bilusic M, Schlom J.

Urol Oncol. 2018 Mar;36(3):93.e1-93.e11. doi: 10.1016/j.urolonc.2017.09.027. Epub 2017 Nov 2.

PMID:
29103968
3.

Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.

Heery CR, Palena C, McMahon S, Donahue RN, Lepone LM, Grenga I, Dirmeier U, Cordes L, Marté J, Dahut W, Singh H, Madan RA, Fernando RI, Hamilton DH, Schlom J, Gulley JL.

Clin Cancer Res. 2017 Nov 15;23(22):6833-6845. doi: 10.1158/1078-0432.CCR-17-1087. Epub 2017 Aug 30.

PMID:
28855356
4.

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.

Heery CR, O'Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M, Lamping E, Oyelakin I, Marté JL, Lepone LM, Donahue RN, Grenga I, Cuillerot JM, Neuteboom B, Heydebreck AV, Chin K, Schlom J, Gulley JL.

Lancet Oncol. 2017 May;18(5):587-598. doi: 10.1016/S1470-2045(17)30239-5. Epub 2017 Mar 31.

PMID:
28373007
5.

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.

Donahue RN, Lepone LM, Grenga I, Jochems C, Fantini M, Madan RA, Heery CR, Gulley JL, Schlom J.

J Immunother Cancer. 2017 Feb 21;5:20. doi: 10.1186/s40425-017-0220-y. eCollection 2017.

6.

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.

Jochems C, Fantini M, Fernando RI, Kwilas AR, Donahue RN, Lepone LM, Grenga I, Kim YS, Brechbiel MW, Gulley JL, Madan RA, Heery CR, Hodge JW, Newton R, Schlom J, Tsang KY.

Oncotarget. 2016 Jun 21;7(25):37762-37772. doi: 10.18632/oncotarget.9326.

7.

A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.

Duggan MC, Jochems C, Donahue RN, Richards J, Karpa V, Foust E, Paul B, Brooks T, Tridandapani S, Olencki T, Pan X, Lesinski GB, Schlom J, Carson Iii WE.

Cancer Immunol Immunother. 2016 Nov;65(11):1353-1364. Epub 2016 Aug 31.

8.

Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial.

Heery CR, Madan RA, Stein MN, Stadler WM, Di Paola RS, Rauckhorst M, Steinberg SM, Marté JL, Chen CC, Grenga I, Donahue RN, Jochems C, Dahut WL, Schlom J, Gulley JL.

Oncotarget. 2016 Oct 18;7(42):69014-69023. doi: 10.18632/oncotarget.10883.

9.

Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy.

Farsaci B, Donahue RN, Grenga I, Lepone LM, Kim PS, Dempsey B, Siebert JC, Ibrahim NK, Madan RA, Heery CR, Gulley JL, Schlom J.

Cancer Immunol Res. 2016 Sep 2;4(9):755-65. doi: 10.1158/2326-6066.CIR-16-0037. Epub 2016 Aug 2.

10.

A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses.

Grenga I, Donahue RN, Lepone LM, Richards J, Schlom J.

Clin Transl Immunology. 2016 May 20;5(5):e83. doi: 10.1038/cti.2016.27. eCollection 2016 May.

11.

Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types.

Lepone LM, Donahue RN, Grenga I, Metenou S, Richards J, Heery CR, Madan RA, Gulley JL, Schlom J.

J Circ Biomark. 2016 Mar 10;5:5. doi: 10.5772/62322. eCollection 2016 Jan-Dec.

12.

Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack.

Grenga I, Kwilas AR, Donahue RN, Farsaci B, Hodge JW.

J Immunother Cancer. 2015 Nov 17;3:52. doi: 10.1186/s40425-015-0096-7. eCollection 2015.

13.

Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.

Heery CR, Ibrahim NK, Arlen PM, Mohebtash M, Murray JL, Koenig K, Madan RA, McMahon S, Marté JL, Steinberg SM, Donahue RN, Grenga I, Jochems C, Farsaci B, Folio LR, Schlom J, Gulley JL.

JAMA Oncol. 2015 Nov;1(8):1087-95. doi: 10.1001/jamaoncol.2015.2736. Erratum in: JAMA Oncol. 2015 Nov;1(8):1171-2.

PMID:
26291768
14.

Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury.

Heery CR, Singh BH, Rauckhorst M, Marté JL, Donahue RN, Grenga I, Rodell TC, Dahut W, Arlen PM, Madan RA, Schlom J, Gulley JL.

Cancer Immunol Res. 2015 Nov;3(11):1248-56. doi: 10.1158/2326-6066.CIR-15-0119. Epub 2015 Jun 30.

15.

Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy.

Kwilas AR, Donahue RN, Tsang KY, Hodge JW.

Cancer Cell Microenviron. 2015;2(1). pii: e677.

16.
17.
18.

Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.

Farsaci B, Donahue RN, Coplin MA, Grenga I, Lepone LM, Molinolo AA, Hodge JW.

Cancer Immunol Res. 2014 Nov;2(11):1090-102. doi: 10.1158/2326-6066.CIR-14-0076. Epub 2014 Aug 4.

19.

A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines.

Donahue RN, Duncan BB, Fry TJ, Jones B, Bachovchin WW, Kiritsy CP, Lai JH, Wu W, Zhao P, Liu Y, Tsang KY, Hodge JW.

Vaccine. 2014 May 30;32(26):3223-31. doi: 10.1016/j.vaccine.2014.04.008. Epub 2014 Apr 13.

20.

Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy.

Kim PS, Jochems C, Grenga I, Donahue RN, Tsang KY, Gulley JL, Schlom J, Farsaci B.

J Immunol. 2014 Mar 15;192(6):2622-33. doi: 10.4049/jimmunol.1301369. Epub 2014 Feb 10.

21.

Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets.

Farsaci B, Jochems C, Grenga I, Donahue RN, Tucker JA, Pinto PA, Merino MJ, Heery CR, Madan RA, Gulley JL, Schlom J.

Int J Cancer. 2014 Aug 15;135(4):862-70. doi: 10.1002/ijc.28743. Epub 2014 Feb 22.

22.

In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer.

Kwilas AR, Donahue RN, Bernstein MB, Hodge JW.

Front Oncol. 2012 Sep 6;2:104. doi: 10.3389/fonc.2012.00104. eCollection 2012.

23.

Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer.

Donahue RN, McLaughlin PJ, Zagon IS.

Exp Biol Med (Maywood). 2012 Feb;237(2):167-77. doi: 10.1258/ebm.2011.011321. Epub 2012 Feb 10.

PMID:
22328595
24.

Expression of the opioid growth factor-opioid growth factor receptor axis in human ovarian cancer.

Fanning J, Hossler CA, Kesterson JP, Donahue RN, McLaughlin PJ, Zagon IS.

Gynecol Oncol. 2012 Feb;124(2):319-24. doi: 10.1016/j.ygyno.2011.10.024. Epub 2011 Oct 28.

PMID:
22037317
25.

Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model.

Donahue RN, McLaughlin PJ, Zagon IS.

Exp Biol Med (Maywood). 2011 Sep;236(9):1036-50. doi: 10.1258/ebm.2011.011121. Epub 2011 Aug 1.

PMID:
21807817
26.

Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.

Donahue RN, McLaughlin PJ, Zagon IS.

Exp Biol Med (Maywood). 2011 Jul;236(7):883-95. doi: 10.1258/ebm.2011.011096. Epub 2011 Jun 17.

PMID:
21685240
27.

The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.

Donahue RN, McLaughlin PJ, Zagon IS.

Gynecol Oncol. 2011 Aug;122(2):382-8. doi: 10.1016/j.ygyno.2011.04.009. Epub 2011 Apr 30.

PMID:
21531450
28.

T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.

Zagon IS, Donahue RN, Bonneau RH, McLaughlin PJ.

Immunobiology. 2011 May;216(5):579-90. doi: 10.1016/j.imbio.2010.09.014. Epub 2010 Sep 29.

PMID:
20965606
29.

B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.

Zagon IS, Donahue RN, Bonneau RH, McLaughlin PJ.

Immunobiology. 2011 Jan-Feb;216(1-2):173-83. doi: 10.1016/j.imbio.2010.06.001. Epub 2010 Jun 11.

PMID:
20598772
30.

Regulation of Tenon's capsule fibroblast cell proliferation by the opioid growth factor and the opioid growth factor receptor axis.

Klocek MS, Sassani JW, Donahue RN, McLaughlin PJ, Zagon IS.

Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5054-61. doi: 10.1167/iovs.09-4949. Epub 2010 May 12.

31.

The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer.

Avella DM, Kimchi ET, Donahue RN, Tagaram HR, McLaughlin PJ, Zagon IS, Staveley-O'Carroll KF.

Am J Physiol Regul Integr Comp Physiol. 2010 Feb;298(2):R459-66. doi: 10.1152/ajpregu.00646.2009. Epub 2009 Nov 18.

32.

Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.

McLaughlin PJ, Zagon IS, Park SS, Conway A, Donahue RN, Goldenberg D.

BMC Cancer. 2009 Oct 18;9:369. doi: 10.1186/1471-2407-9-369.

33.

Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.

Zagon IS, Donahue RN, McLaughlin PJ.

Am J Physiol Regul Integr Comp Physiol. 2009 Oct;297(4):R1154-61. doi: 10.1152/ajpregu.00414.2009. Epub 2009 Aug 12.

34.

Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.

Donahue RN, McLaughlin PJ, Zagon IS.

Am J Physiol Regul Integr Comp Physiol. 2009 Jun;296(6):R1716-25. doi: 10.1152/ajpregu.00075.2009. Epub 2009 Mar 18.

35.

Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function.

Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ.

Exp Biol Med (Maywood). 2008 Aug;233(8):968-79. doi: 10.3181/0802-RM-58. Epub 2008 May 14.

PMID:
18480416

Supplemental Content

Loading ...
Support Center